In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y.

Joshi M, Kelsey M, ACP Journal Club Editorial Team at McMaster University

Open source

DOI
10.7326/annals-26-03105-jc
Published
2026 Sep
Container
Annals of internal medicine
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7326/annals-26-03105-jc,
  title = {In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y.},
  author = {Joshi M and Kelsey M and ACP Journal Club Editorial Team at McMaster University},
  year = {2026},
  journal = {Annals of internal medicine},
  doi = {10.7326/annals-26-03105-jc},
  url = {https://doi.org/10.7326/annals-26-03105-jc}
}

RIS

TY  - JOUR
TI  - In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y.
AU  - Joshi M
AU  - Kelsey M
AU  - ACP Journal Club Editorial Team at McMaster University
PY  - 2026
JO  - Annals of internal medicine
DO  - 10.7326/annals-26-03105-jc
UR  - https://doi.org/10.7326/annals-26-03105-jc
ER  - 

APA

M, J., M, K., & University, A. J. C. E. T. A. M. (2026). In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y.. Annals of internal medicine. https://doi.org/10.7326/annals-26-03105-jc

Source records